OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70057 ↗Kurz gefasst
Fallbericht in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Wen Xiong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Osteomyelitis, Osteoclasts, Osteogenesis, Tumor Necrosis Factor Inhibitors. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To verify the pathogenesis of the OGFRL1 loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a CRMO patient and investigate the underlying mechanism.
Methods
Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant. qPCR, ELISA, CBA, bulk RNA sequencing and single‐cell RNA sequencing were conducted to detect the inflammatory signatures of the patient versus healthy controls. Collagen antibody‐induced arthritis model was generated in Ogfrl1 knockout (KO) and wild‐type (WT) mice and micro‐CT scan was performed to investigate the pathogenicity of Ogfrl1 deficiency. In addition, osteoclast induction and differentiation in vitro was exerted to explore the underlying mechanism of Ogfrl1 deficiency.
Results
The patient exhibited upregulated MAPK and NF‐κB signaling pathways, along with overproduction of proinflammatory cytokines. Compared to healthy controls, apparent activation of myeloid cells was observed, especially in monocytes, dendritic cells, and low‐density granulocytes (LDGs) of the patient. In the collagen antibody‐induced arthritis (CAIA) model, Ogfrl1 KO mice developed more severe and persistent arthritis and bone erosion than WT mice. Ogfrl1 KO mice were more prone to osteoclast differentiation versus WT mice. The patient responded well to TNF inhibitor therapy, with normalization of CRP, ESR, and SAA, and IL‐6 levels, as well as improvement in osteolytic lesions.
Conclusion
This study identified OGFRL1 deficiency as a novel cause of CRMO, highlighted the previously unrecognized role of OGFRL1 in restraining inflammatory responses, and provided novel insights into the pathogenesis and treatment of this autoinflammatory disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China.
- Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and Liangzhu Laboratory of Zhejiang University, Hangzhou, Zhejiang, China.
- Department of Rheumatology and Immunology, Shenzhen Children's Hospital affiliated Shantou University Medical College, Shantou University, Shenzhen, China.
- Life Sciences Institute, Zhejiang University, Hangzhou, China.
ORCID-Profile: Xiaomin Yu, Qing Zhou
Zitieren
APA
Xiong, W., Wang, Y., He, T., Fu, J., Luo, Y., Wang, J., Wang, J., Yu, X., Zhou, Q., & Yang, J. (2026). OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor. Arthritis & Rheumatology. https://doi.org/10.1002/art.70057
Vancouver
Xiong W, Wang Y, He T, Fu J, Luo Y, Wang J, et al. OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor. Arthritis & Rheumatology. 2026. doi:10.1002/art.70057
BibTeX
@article{Xiong2026,
author = {Xiong, Wen and Wang, Yusha and He, Tingyan and Fu, Jinjian and Luo, Ying and Wang, Jinbo and Wang, Jun and Yu, Xiaomin and Zhou, Qing and Yang, Jun},
title = {OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70057}
}
EUVIMED